Document:

<PAGE>
                                                                   EXHIBIT 10.35

                              CERIDIAN CORPORATION
                           DEFERRED COMPENSATION PLAN

                         FOURTH DECLARATION OF AMENDMENT

Pursuant to the retained power of amendment contained in Section 6.2 of the
Ceridian Corporation Deferred Compensation Plan, the undersigned hereby amends
the Plan in the manner desribed below.

1.    Section 3.2(e) of the Plan is amended to read as follows:

      (e)   Timing of Credits. Deferrals of an Active Participant's Base
            Compensation, Annual Bonus and Eligible Long-Term Bonus pursuant to
            this section will be credited to his or her Participant Deferral
            Account as of the last day of the calendar month first following the
            date on which the Participant would have otherwise received the Base
            Compensation, Annual Bonus or Eligible Long-Term Bonus but for his
            or her deferral election pursuant to this section.

2.    Section 3.4(j)(viii)(2) of the Plan is amended to read as follows:

      (2)   CHANGE OF CONTROL. "Change of Control" shall mean the first of the
following events to occur:

            (A) there is consummated a merger or consolidation to which the
Company or any direct or indirect subsidiary of the Company is a party if the
merger or consolidation would result in the voting securities of the Company
outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity or any parent thereof) less than 60% of the
combined voting power of the securities of the Company or such surviving entity
or any parent thereof outstanding immediately after such merger or
consolidation; or

            (B) the direct or indirect beneficial ownership (as defined in Rule
13d-3 under the Securities Exchange Act of 1934) in the aggregate of securities
of the Company representing (20%) or more of the total combined voting power of
the Company 's then issued and outstanding securities is acquired by any person
or entity or group of associated persons or entities acting in concert;
provided, however, that for purposes of hereof, the following acquisitions shall
not constitute a Change of Control: (I) any acquisition by the Company or any of
its subsidiaries, (II) any acquisition directly from the Company or any of its
subsidiaries, (III) any acquisition by any employee benefit plan (or related
trust or fiduciary) sponsored or maintained by the Company or any corporation
controlled by the Company, (IV) any acquisition by an underwriter temporarily
holding securities pursuant to an offering of such securities, (V) any

<PAGE>
acquisition by a corporation owned, directly or indirectly, by the stockholders
of the Company in substantially the same proportions as their ownership of stock
of the Company (VI) any acquisition in connection with which, pursuant to Rule
13d-1 promulgated pursuant to the Exchange Act, the individual, entity or group
is permitted to, and actually does, report its beneficial ownership on Schedule
13-G (or any successor Schedule); provided that, if any such individual, entity
or group subsequently becomes required to or does report its beneficial
ownership on Schedule 13D (or any successor Schedule), then, for purposes of
this paragraph, such individual, entity or group shall be deemed to have first
acquired, on the first date on which such individual, entity or group becomes
required to or does so report, beneficial ownership of all of the voting
securities of the Company beneficially owned by it on such date, and (VII) any
acquisition in connection with a merger or consolidation which, pursuant to
paragraph (A) above, does not constitute a Change of Control; or

      (C) there is consummated a transaction contemplated by an agreement for
the sale or disposition by the Company of all or substantially all of the
Company 's assets, other than a sale or disposition by the Company of all or
substantially all of the Company 's assets to an entity, at least 60% of the
combined voting power of the voting securities of which are owned by
stockholders of the Company in substantially the same proportions as their
ownership of the Company immediately prior to such sale; or

      (D) the stockholders of the Company approve any plan or proposal for the
liquidation of the Company; or

      (E) a change in the composition of the Board such that the "Continuity
Directors" cease for any reason to constitute at least a majority of the Board.
For purposes of this clause, "Continuity Directors" means those members of the
Board who either (I) were directors on January 29, 2002, or (II) were elected
by, or on the nomination or recommendation of, at least a two-thirds (2/3)
majority of the then-existing Board (other than a director whose initial
assumption of office was in connection with an actual or threatened election
contest, including but not limited to a consent solicitation, relating to the
election of directors of the Company); or

      (F) such other event or transaction as the Board shall determine
constitutes a Change of Control.

3.    A new Sub-Section (D) is added to Section 6.2 as follows:

      (D) Notwithstanding anything in the Plan to the contrary, from and after
the occurrence of a Change of Control, no amendment may be made to the Plan that
would adversely affect the terms and conditions associated with the Account
balance of any Participant as of the date of the Change of Control.

The foregoing amendments are effective as of January 29, 2002.

                                       2
<PAGE>
The undersigned has caused this instrument to be executed by its duly authorized
officers this 29th day of January, 2002.

                                            CERIDIAN CORPORATION

Attest: /s/ William E. McDonald             By /s/ Shirley J. Hughes
        ----------------------------           ---------------------------------
        Deputy Secretary                       Senior Vice President

                                       3<PAGE>

AGREEMENT

1. PARTIES

The parties to this Agreement are:

1.1 Samir M. Henalla, M.R.C.O.G. ("HENALLA") having a principal residence at
Highfield Hall, 306 Barnsley Road, Sandal, Wakefield, WF2 6AX, United Kingdom;
and

1.2 Uroplasty, Inc. ("UROPLASTY"), a corporation organized under the laws of the
state of Minnesota, having a principal place of business at 27 18 Summer Street
N.E., Minneapolis, Minnesota, 55413-2820.

2. BACKGROUND

2.1 HENALLA is the inventor of an invention disclosed in U.S. Patent Application
Ser. No. 09/040,594, filed 18 March 1998, which is a Continuation-In-Part of
U.S. Patent Application Ser. No. 08/752,038, filed 19 November 1996, entitled
"INSTRUMENT FOR GUIDING DELIVERY OF INJECTABLE MATERIALS IN TREATING URINARY
INCONTINENCE."

2.2 UROPLASTY has obtained an absolute assignment from HENALLA of the entire
right, title, and interest in the PATENT RIGHTS, as defined below, including
without limitation the right to make, have made, use, offer for sale, and sell
the ASSIGNED PRODUCT, as defined below.

3. CONSIDERATION

This Agreement is entered into in consideration of the purposes and mutual
covenants expressed herein, the sufficiency and adequacy of which are
acknowledged by the parties.

4. DEFINITIONS

For the purpose of this Agreement, the following definitions apply:

4.1 "PATENT RIGHTS" shall mean the entire right, title and interest for the
United States and all foreign countries in and to any and all inventions which
are disclosed in U. S. Patent Application Ser. Nos. 09/040,594 and 08/752,038
entitled "INSTRUMENT FOR GUIDING DELIVERY OF INJECTABLE MATERIALS IN TREATING
URINARY INCONTINENCE," such applications and all divisional, continuing,
substitute, renewal, reissue and all other applications for patent which have
been or shall be filed in the United States and all foreign countries on any of
such inventions; all original and reissued patents which have been or shall be
issued in the United States and all foreign countries (including U.K. Patent No.
2,284,158) on such inventions; and specifically including the right to file
foreign applications under the provisions of any convention or treaty and claim
priority based on such application in the United States.

                                       1

<PAGE>

4.2 "AFFILIATE" shall mean any corporation or organization which directly or
indirectly controls, is controlled by or is under common control with UROPLASTY;
control being the ownership of at least forty percent (40%) of the stock
entitled to vote upon election of directors thereof.

4.3 "SOLD' (or "SALE") shall mean sold or otherwise disposed of for value by
UROPLASTY or AFFILIATE, but excluding sales among and between UROPLASTY and
AFFILIATES.

4.4 "ASSIGNED PRODUCT" shall mean any and all instruments covered by the PATENT
RIGHTS or otherwise embodying an invention covered by the PATENT RIGHTS, which
is a product Sold by UROPLASTY or AFFILIATE under conditions or circumstances
which, if unassigned, would otherwise constitute infringement of the PATENT
RIGHTS.

4.5 "INVENTION" shall mean any device, method, process, or improvement disclosed
U.S. Patent Application Ser. Nos. 09/040,594 and 08/752,038.

5. DISTRIBUTORS

5.1 UROPLASTY and AFFILIATES shall have the right at any time to grant the right
to distribute the ASSIGNED PRODUCT to any other party or parties for resale
distribution upon such terms and conditions as UROPLASTY shall determine.

5.2 HENALLA shall be entitled to receive from UROPLASTY and AFFILIATES the
royalty pursuant to Section 7 with respect to sales of ASSIGNED PRODUCT made to
such distributors and not upon subsequent sales made by any distributors.

6. COSTS AND PATENT DISCLOSURE

6.1 UROPLASTY shall bear the costs of obtaining and maintaining U.S. and other
jurisdiction patents for ASSIGNED PRODUCT. UROPLASTY shall, in its sole
discretion, decide whether to pursue or maintain any patent which falls within
the scope of PATENT RIGHTS.

6.2 UROPLASTY agrees to provide HENALLA with full disclosure relating to issued
Patents claims and all related reissued Patents, continuations, and divisional
applications related thereto. HENALLA agrees that all patent claims, supporting
data, know how, and documentation is confidential and shall not be disclosed to
third parties without the expressed written consent of UROPLASTY.

7. ROYALTIES. RECORDS AND REPORTS

7.1 UROPLASTY shall pay to HENALLA royalties at the rate of 10 British Pounds
per unit sold by it to both direct customers and to UROPLASTY's distributors.

7.2 Upon the sale or licensing or other disposal of the manufacturing rights to
the ASSIGNED PRODUCT by UROPLASTY to a third party, UROPLASTY shall ensure that
HENALLA shall continue to receive 10 British pounds per unit sold by such third
party as per the terms of this Agreement.

                                       2

<PAGE>

7.3 Royalties shall be paid quarterly on the last day of each of the months of
August, November, February, and May for the ASSIGNED PRODUCT for the three month
period ending the last day of each fiscal quarter ending June, September,
December, and March. Each payment shall be accompanied by documentation
supporting the determination of the royalty payment amount.

7.4 UROPLASTY shall keep accurate books of account containing information which
may be necessary for the purpose of showing the amount payable to HENALLA under
this Agreement. Said books of account shall be kept at UROPLASTY's principal
place of business. Said books and the supporting data shall be open at
reasonable times, for two (2) years following the end of the calendar year to
which they pertain (and access shall not be denied thereafter, if reasonably
available), for inspection by an independent certified public accountant
retained by HENALLA and reasonably acceptable to UROPLASTY for the purpose of
verifying UROPLASTY's determination of royalties earned.

7.5 All amounts payable hereunder by UROPLASTY to HENALLA shall be payable in
British Pounds to HENALLA's designated account at the Halifax Building Society
in the United Kingdom.

7.6 All payments under this Agreement shall be made in full without deduction of
taxes, charges, or any other duties that may be imposed, except to the extent
that credit may be obtained for such taxes, charges, or duties against HENALLA's
tax payable on such sums either: (a) under a double taxation convention between
the government of the United Kingdom and the United States; or (b) under
unilateral provisions for granting such credit in the legislation of the United
Kingdom. UROPLASTY will not be obligated to withhold any taxes, charges, or
duties, nor be otherwise responsible for establishing credit for such taxes,
charges, or duties, associated with any payments to HENALLA under this
Agreement.

7.7 UROPLASTY shall provide HENALLA with certificates of tax deducted from the
payments made under this Agreement, duly certified by relevant authorities, in
the event that UROPLASTY is required by relevant authorities to deduct such
taxes.

8. BEST EFFORTS COMMERCIALIZATION

UROPLASTY agrees to use its best efforts to develop, manufacture, commercialize,
and sell the Assigned Product.

9. TECHNICAL ASSISTANCE

9.1 HENALLA agrees to reasonably assist UROPLASTY with creation of applicable
package labeling and product insert technical data for the ASSIGNED PRODUCT and
with clinical data per European Committee for Standardization, Adopted European
Standard, EN 5,40: 1993, Clinical Investigation of Medical Devices for Human
Subjects, date of ratification (dor): 1993-06-21.

                                       3

<PAGE>

9.2 UROPLASTY will reimburse pre-approved expenses of HENALLA for assistance
requested by UROPLASTY and acknowledges that HENALLA shall not be held liable
for any loss arising out of HENALLA's acts in providing technical assistance to
UROPLASTY.

10. DURATION

This Agreement takes effect immediately and shall continue until the date of
expiry of the longest-lasting issued patent relating to the ASSIGNED PRODUCT.

11. ASSIGNMENT

The provisions of this Agreement shall inure to the benefit of, and be binding
upon, the executors, administrators, heirs, distributees and assigns of the
parties hereto.

12. LITIGATION

12.1 HENALLA agrees to cooperate with UROPLASTY to protect any Patents within
the PATENT RIGHTS from infringement and, if necessary, testify. UROPLASTY agrees
to compensate HENALLA for such cooperation solely in the form of reimbursement
for any out-of-pocket costs incurred by HENALLA in cooperating with UROPLASTY.

12.2 UROPLASTY in its sole discretion may decide whether to initiate suit
against an alleged infringer.

12.3 Any sums recovered from an infringer by way of damages, account of profits,
attorneys fees, costs, or any other recovery shall belong to UROPLASTY only.

13. INDEMNIFICATION

UROPLASTY agrees to indemnify and hold HENALLA harmless against any and all
liability, damages, costs and expenses, including attorney's fees, incurred by
HENALLA by reason of any claim, alleged or actual defect or insufficient design,
materials or workmanship, or package labeling or product insert technical data
instructions for use in the production or sale of ASSIGNED PRODUCT.

14. DOCUMENTS AND OTHER OBLIGATIONS

14.1 HENALLA at UROPLASTY's request shall execute all documents deemed
reasonably necessary to evidence, record, or protect UROPLASTY's PATENT RIGHTS.

14.2 HENALLA agrees to carry out in good faith the intent and purpose of this
Agreement.

14.3 HENALLA agrees to execute all divisional, continuing, substitute, renewal,
reissue, and all other patent applications on any and all such improvements;
execute all rightful oaths, declarations, assignments, powers of attorney and
other papers; communicate to UROPLASTY all facts known to the undersigned
relating to such improvements and the history thereof; and generally do
everything possible which UROPLASTY shall consider desirable for vesting title
to such improvements in UROPLASTY, and for securing, maintaining and enforcing
proper patent protection for such improvements.

                                       4

<PAGE>

14.4 HENALLA covenants not to knowingly engage in activity that would in any way
diminish the value of the PATENT RIGHTS transferred to UROPLASTY.

14.5 UROPLASTY agrees to compensate HENALLA for actions performed by HENALLA
under the terms of Sections 14.1 and 14.3 solely in the form of reimbursement
for any out-of-pocket costs incurred by HENALLA in performing such actions for
UROPLASTY.

15. ALTERNATIVE DISPUTE RESOLUTION

15.1 DISPUTE DEFINED. A "Dispute" within the meaning of this ADR Section 15
shall be any dispute or disagreement between the parties to this Agreement which
relates to or arises out of this Agreement or the validity, enforcement,
performance, breach, termination or construction of this Agreement.

15.2 INITIATION OF THE ADR PROCESS. Either party may initiate the ADR dispute
resolution process of this Section 15, at any time, by giving Written Notice to
the other party, describing in general terms the nature of the Dispute, the
initiating party's claim for relief, and identifying by name, address, telephone
and fax numbers one or more essentially-available individuals with authority to
settle the Dispute on such party's behalf.

15.4 NEGOTIATION. The parties agree that if any Dispute occurs, they will
attempt, prior to the commencement or conduct of litigation of such Dispute to
resolve that Dispute amicably by timely negotiation between promptly appointed
and fully authorized personnel.

15.5 MEDIATION. If for any reason the Dispute is not settled within 45 days of
such initiating Written Notice (which time the parties may extend or shorten by
mutual agreement), then the parties shall endeavor in good faith to settle the
Dispute by mediation under the then current rules except as herein modified, of
the International Chamber of Commerce Court of Arbitration, hereinafter "ICC,"
whose present address is 38, Cours Albert ler, 75008 Paris, France.

15.6 ARBITRATION. If the Dispute is not settled by mediation within fifteen days
after the mediation or any agreed change of that term, then the Dispute shall be
settled by binding arbitration in accordance with the then current ICC Rules by
a sole arbitrator whom shall be appointed by the parties.

16. MISCELLANEOUS

16.1 This Agreement constitutes the entire agreement between the parties hereto
and hereby revokes and supersedes all prior agreements between the parties
relating to the PATENT RIGHTS, with the exception of the absolute assignment
referenced above in Section 2.2. No waiver or modification of the terms hereof
shall be valid unless in writing and signed by the parties and then only to the
extent therein provided.

                                       5

<PAGE>

16.2 Any notice required or permitted to be given by this Agreement shall be
given by postpaid, first class, registered or certified mail addressed to:

Samir M. Henalla, M.R.C.O.G
Highfield Hall
306 Barnsley Road
Sandal, Wakefield, WF26AX
UNITED KINGDOM

OR

Uroplasty, Inc.
2718 Summer Street N.E.
Minneapolis, MN 554 13
UNITED STATES

Such addresses may be altered by notice so given. If no time limit is specified
for a notice required or permitted to be given by this Agreement, the time limit
therefore shall be five (5) full business days, not including the day of
mailing.

16.3 The law applicable to this Agreement is the law of England and Wales and
the Parties hereby submit to the jurisdiction of the Courts of England and
Wales.

16.4 Any dispute or controversy arising out of or relating to this Agreement,
its construction or its actual or alleged breach, shall be resolved according to
the ADR dispute resolution provisions set forth in Section 15.

16.5 Nothing in this Agreement shall be construed so as to require the
commission of any act contrary to law, and wherever there is any conflict
between any provision of this Agreement and any statute, law, ordinance or
treaty concerning the legal right of the parties to contract, the latter shall
prevail, but in such event the affected provisions of this Agreement shall be
curtailed and limited only to the extent necessary to bring it within the
applicable legal requirements.

16.6 Should any clause, term or provision of this Agreement be held to be
illegal or in conflict with any law, the validity of the remaining clauses,
terms and provisions of this Agreement shall not be affected thereby, and
parties hereto expressly stating they would have entered into this Agreement had
any such clause, term or provision been omitted therefrom.

16.7 Failure by any party at any time to require performance of any provision of
this Agreement shall not affect the right of the party requiring performance to
require full performance thereafter, and a waiver by any party of a breach of
any provision of this Agreement shall not be taken or held to be a waiver of any
further or similar breach or as nullifying the effectiveness of such provision.

                                       6

<PAGE>

IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals
and duly executed this Agreement on the date(s) indicated below, to be effective
the lattermost date on which the Agreement is executed by either party.

UROPLASTY, INC. (UROPLASTY)                      SAMIR M. HENALLA (HENALLA)

By:  /s/ Daniel G. Holman                        By: /s/ Samir M. Henalla
    ---------------------------------               ----------------------------
     Chairman and CEO

Date:  October 14, 1998                          Date:  October 6, 1998

Attest: /s/ Linda L. Westberg                    Attest: /s/ Fiona Joy Waldoch

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]